Rehovot, Israel – August 3, 2015 – Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the
improvement of crop productivity and economics for the food and feed industries, announced today that Assaf Oron, Executive Vice President for Strategy and Business Development, will participate at the Piper Jaffray Technology-Enabled Industrials Symposium taking place in Minneapolis, Minnesota, August 4 and 5, 2015. Mr. Oron will take part at the conference Ag Biotech and the Future of Crop Science panel which will take place on Wednesday, August 5, at 11:00 am. Investors or potential partners attending the conference, who wish to meet with Mr. Oron, may contact Evogene’s Investor Relations team at investors@evogene.com.
-xxx-
About Evogene Ltd.:
Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and
economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com.
This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differmaterially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene’s control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact:
Karen Mazor, Evogene
Director, Public and Investor Relations
T: +972-54-2288 039
karen.mazor@evogene.com